News | August 10, 2021
SMS Pharmaceuticals revenue grows by 44%; Profit up 235%
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Filing for WHO Emergency Use Authorisation this month
Deal for 100 million doses with additional 100 million through 2023
It is part of the company’s pain/analgesics portfolio of OTC products
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
